Bayer Detailed Consensus >> Segments
Consensus as of: 2026-11-13

Please note:

  • Historic numbers for FY 2025 are restated according to the new Core EPS methodology
  • The estimates for FY 2026-30 are taking the new Core EPS methodology into account as well

KPI[EUR m]FY 2025FY 2026 EFY 2027 EFY 2028 EFY 2029 EFY 2030 E
Pharmaceuticals, SalesNumber of Estimates1514141110
Pharmaceuticals, SalesHighest18,29319,52321,33823,39025,184
Pharmaceuticals, SalesAverage17,82918,10618,88719,80020,87122,084
Pharmaceuticals, SalesMedian18,14818,88119,84721,06822,373
Pharmaceuticals, SalesLowest17,67618,15318,51018,82319,086
XareltoNumber of Estimates10101099
XareltoHighest1,5091,3311,198994944
XareltoAverage2,3441,4771,068890763695
XareltoMedian1,4711,061899776705
XareltoLowest1,453912671509399
EyleaNumber of Estimates10101099
EyleaHighest2,3212,1792,0701,8811,825
EyleaAverage3,1102,2982,0491,8421,6831,584
EyleaMedian2,3012,0291,8131,6581,615
EyleaLowest2,2621,9301,7351,5261,297
Nubeqa & KerendiaNumber of Estimates10101099
Nubeqa & KerendiaHighest5,1776,9458,3489,58510,753
Nubeqa & KerendiaAverage3,2145,0646,4297,4488,1288,830
Nubeqa & KerendiaMedian5,0616,3897,4468,0788,798
Nubeqa & KerendiaLowest4,9595,8406,6097,2127,706
NubeqaNumber of Estimates10101099
NubeqaHighest3,7534,9935,7426,2386,737
NubeqaAverage2,3853,6864,5635,1595,4335,765
NubeqaMedian3,6824,4875,1445,6585,856
NubeqaLowest3,6294,1114,5754,7545,140
Kerendia (Finerenone)Number of Estimates10101099
Kerendia (Finerenone)Highest1,4242,0202,6783,3474,016
Kerendia (Finerenone)Average8291,3781,8662,2892,6953,065
Kerendia (Finerenone)Median1,3831,8632,2952,6833,005
Kerendia (Finerenone)Lowest1,3291,7281,8872,3252,455
New Launch AssetsNumber of Estimates66666
New Launch AssetsHighest3799421,5402,3373,084
New Launch AssetsAverage02837021,2991,8992,454
New Launch AssetsMedian2806791,2881,8972,484
New Launch AssetsLowest2085801,0791,4581,783
Lynkuet (Elinzanetant)Number of Estimates77777
Lynkuet (Elinzanetant)Highest1655138511,2381,564
Lynkuet (Elinzanetant)Average0100216348487609
Lynkuet (Elinzanetant)Median90165267347417
Lynkuet (Elinzanetant)Lowest5095152217300
Sunharbo (Asundexian)Number of Estimates88888
Sunharbo (Asundexian)Highest181706751,3501,800
Sunharbo (Asundexian)Average03123386660953
Sunharbo (Asundexian)Median0153363588900
Sunharbo (Asundexian)Lowest017112209375
Beyonttra (Acoramidis)Number of Estimates66666
Beyonttra (Acoramidis)Highest216385560784980
Beyonttra (Acoramidis)Average0189360539703836
Beyonttra (Acoramidis)Median198354541690807
Beyonttra (Acoramidis)Lowest140350515618711
Base BusinessNumber of Estimates66666
Base BusinessHighest9,1528,9879,0189,2199,535
Base BusinessAverage9,1629,0438,7438,6748,7048,802
Base BusinessMedian9,0218,7468,6708,7228,822
Base BusinessLowest8,9238,4888,2758,0557,865
t/o IUD FamilyNumber of Estimates10101099
t/o IUD FamilyHighest1,3871,4661,5401,6171,698
t/o IUD FamilyAverage1,3661,3681,4031,4201,4421,460
t/o IUD FamilyMedian1,3681,3971,4031,4181,433
t/o IUD FamilyLowest1,3491,3691,3611,3661,345
t/o HEM Franchise Number of Estimates10101099
t/o HEM Franchise Highest2,0572,0412,0232,0222,010
t/o HEM Franchise Average613686656625607581
t/o HEM Franchise Median533501471434403
t/o HEM Franchise Lowest527477431389351
t/o AdalatNumber of Estimates10101099
t/o AdalatHighest595635664685706
t/o AdalatAverage503576577578581583
t/o AdalatMedian575576580573573
t/o AdalatLowest551470444456450
t/o Aspirin CardioNumber of Estimates99988
t/o Aspirin CardioHighest509658644642642
t/o Aspirin CardioAverage516478499496493493
t/o Aspirin CardioMedian482482499508514
t/o Aspirin CardioLowest448425384346312
t/o AdempasNumber of Estimates10101099
t/o AdempasHighest773812853793803
t/o AdempasAverage745757561451342301
t/o AdempasMedian760547406299274
t/o AdempasLowest738329195136130
Pharmaceuticals, EBITDA before special itemsNumber of Estimates1514141110
Pharmaceuticals, EBITDA before special itemsHighest4,8345,1635,7016,5497,555
Pharmaceuticals, EBITDA before special itemsAverage4,5254,7074,8855,2865,8476,445
Pharmaceuticals, EBITDA before special itemsMedian4,7304,9255,3916,0046,684
Pharmaceuticals, EBITDA before special itemsLowest4,4194,6104,7204,8474,962
Consumer Health, SalesNumber of Estimates151414109
Consumer Health, SalesHighest5,9446,2046,4246,6516,887
Consumer Health, SalesAverage5,8025,8846,0816,2526,4516,629
Consumer Health, SalesMedian5,8816,0906,2426,4346,596
Consumer Health, SalesLowest5,8275,9396,0146,2946,464
Consumer Health, EBITDA before special itemsNumber of Estimates151414109
Consumer Health, EBITDA before special itemsHighest1,4181,5311,6051,6821,803
Consumer Health, EBITDA before special itemsAverage1,3411,3341,4261,4871,5591,625
Consumer Health, EBITDA before special itemsMedian1,3311,4211,4781,5491,606
Consumer Health, EBITDA before special itemsLowest1,2921,3501,3731,4721,502
CropScience, SalesNumber of Estimates151414109
CropScience, SalesHighest22,06222,67923,67124,48225,605
CropScience, SalesAverage21,62221,72122,19522,90123,79824,649
CropScience, SalesMedian21,70422,17122,82923,71324,631
CropScience, SalesLowest21,23221,75022,38323,07923,969
CropScience, EBITDA before special itemsNumber of Estimates151414109
CropScience, EBITDA before special itemsHighest4,7705,1815,5395,9976,224
CropScience, EBITDA before special itemsAverage4,1884,5674,7425,1045,5035,816
CropScience, EBITDA before special itemsMedian4,5604,7035,0635,4785,760
CropScience, EBITDA before special itemsLowest4,2644,4944,8215,1445,513
Reconciliation, SalesNumber of Estimates151414109
Reconciliation, SalesHighest328336344362356
Reconciliation, SalesAverage322302299302314311
Reconciliation, SalesMedian319321321322322
Reconciliation, SalesLowest254208220238238
Reconciliation, EBITDA before special itemsNumber of Estimates14131398
Reconciliation, EBITDA before special itemsHighest-522-368-400-500-445
Reconciliation, EBITDA before special itemsAverage-385-571-540-547-552-549
Reconciliation, EBITDA before special itemsMedian-568-505-500-545-550
Reconciliation, EBITDA before special itemsLowest-643-774-792-618-625
Disclaimer

This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.